OncLive® On Air cover image

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

OncLive® On Air

00:00

Epcot-Nhl1 Trial and Role in Large B-Sil Lymphoma

This will be for third line and beyond if you start to be seldom foma, so in that setting, we do have all three CAR-T products. For the majority of the country, there aren't any CAR-T centers in a general vicinity or area. And given the overall response rate in the CR-8 and the durability of response of this treatment, this does provide probably a better alternative to some of the other agents that are approved in this setting.

Play episode from 02:44
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app